**Precision medicine in COPD: review of mepolizumab for eosinophilic COPD**

**Introduction**

Precision medicine for chronic obstructive pulmonary disease (COPD) can improve management for those who may have otherwise exhausted conventional therapy. Approximately 40% of patients with COPD have a persistently elevated blood eosinophil count ≥150 cells·μL⁻¹ [1]. Blood eosinophils are reflective of sputum eosinophil count, which is used as a marker of eosinophilic airway inflammation [2, 3]. Debatably, raised blood eosinophils identify a distinct COPD phenotype with increased frequency and severity of exacerbations [4–6]. Guiding corticosteroid treatment according to the level of blood eosinophils results in a reduction in exacerbations, which is indicative of its value as a biomarker of corticosteroid responsiveness [7–9]. However, the use of inhaled corticosteroids has been associated with increased risk of pneumonia [10, 11].

Previous studies have investigated the potential for targeted monoclonal antibody therapy for COPD. BRIGHTLING et al. [12] studied benralizumab, an interleukin (IL)-5 receptor antibody. IL-5 stimulates growth, maturation and release of eosinophils and precipitates their survival to allow ongoing inflammatory response. *Post hoc* analysis comparing the effects of benralizumab on a subgroup of patients with raised blood eosinophils found a significant improvement in lung function, but no effect on exacerbation rate [12].

Mepolizumab is a monoclonal antibody to IL-5. Mepolizumab has been well documented to reduce eosinophilic inflammation and exacerbations in severe asthmatic patients with raised blood and sputum eosinophils [13–15]. To this end, PAVORD et al. [16] explored the impact of mepolizumab on frequently exacerbating COPD patients, on maximal triple inhaled therapy, with raised blood eosinophils. Here, we analyse the study and findings, and its impact on clinical practice.

**Study design**

The study by PAVORD et al. [16] was constructed into two multicentre, phase 3, randomised,
placebo-controlled, double-blind, parallel-group trials: mepolizumab versus placebo as add-on treatment for frequently exacerbating COPD patients (METREX), and mepolizumab versus placebo as add-on treatment for frequently exacerbating COPD patients characterised by eosinophil level (METREO). Table 1 summarises the key study characteristics and methods.

Patients were aged ≥40 years with at least a 1-year diagnosis of COPD, taking maximal triple inhaled therapy, and who had a history of two or more moderate exacerbations (treated with systemic corticosteroids and/or treatment with antibiotics) or one severe exacerbation (required hospitalisation) in the previous year.

Table 1  Key study characteristics and methods

| Characteristic                  | METREX                                      | METREO                                      |
|--------------------------------|---------------------------------------------|---------------------------------------------|
| Population                     | All patients receiving ≥1 dose of mepolizumab or placebo | Patients with blood eosinophils ≥150 cells·μL⁻¹ at screening or ≥300 cells·μL⁻¹ | Patients with blood eosinophils ≥150 cells·μL⁻¹ at screening or ≥300 cells·μL⁻¹ |
| Intervention 1                 | Mepolizumab 100 mg s.c. (n=417)             | Mepolizumab 100 mg s.c. (n=233)             | Mepolizumab 100 mg s.c. (n=223) |
| Intervention 2                 | Placebo (0.9% saline) s.c. (n=419)          | Placebo (0.9% saline) s.c. (n=229)          | Placebo (0.9% saline) s.c. (n=226) |
| Key inclusion criteria         | COPD diagnosis: history of COPD for ≥1 year in accordance with the definition provided by the American Thoracic Society/European Respiratory Society [17] | FEV₁ to FVC ratio <0.70 before and after bronchodilator use and a post-bronchodilator FEV₁ >20% and ≤80% of the predicted value | ≥2 moderate COPD exacerbations (use of systemic corticosteroids and/or treatment with antibiotics) or ≥1 severe COPD exacerbation (required hospitalisation) |
|                               | Triple inhaled therapy for at least 12 months prior to screening including 3 months of an ICS at dose ≥500 μg·day⁻¹ fluticasone propionate dose equivalent, plus LABA and LAMA; or must be taking for 12 months prior to screening (but not in 3 months immediately prior) ICS plus LABA or LAMA and a phosphodiesterase-4 inhibitor, methylxanthine, or a combination of short-acting β₂-agonist and short-acting muscarinic antagonist | ≥40 years of age at screening | Confirmed COPD with no restrictions on smoking status (smoker, nonsmoker, never-smoker) |
| Key exclusion criteria         | Current diagnosis of asthma                 | Previous history of asthma in never-smokers | Other respiratory disorders, including α₁-antitrypsin deficiency, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases |
|                               | Pneumonia, exacerbation, lower respiratory tract infection within 4 weeks prior to screening | Other conditions causing elevated eosinophils or parasitic infection |
| Randomisation                  | Computer-generated, permuted block          |                                             |                                             |
| Analysis                       | Intention-to-treat                          |                                             |                                             |
| Primary end-point              | Time to first exacerbation                  | Emergency department visits                 | Hospitalisation                             |
| Secondary end-points           | Average yearly change in St George’s Respiratory Questionnaire score | Average yearly change in COPD Assessment Test score |
| Pre-specified meta-analysis    | Blood eosinophil stratification based on the following thresholds: <150 and a history of ≥300 cells·μL⁻¹ in the previous year; ≥150 to <300 cells·μL⁻¹; ≥300 to <500 cells·μL⁻¹; and ≥500 cells·μL⁻¹ | Blood eosinophils <150 cells·μL⁻¹, blood eosinophils ≥300 cells·μL⁻¹ |
| Post hoc meta-analysis         | Blood eosinophils <150 cells·μL⁻¹, blood eosinophils ≥300 cells·μL⁻¹ | Effect of mepolizumab compared to placebo on moderate/severe exacerbations treated with glucocorticoids (alone or in addition to antibiotics), or those treated with antibiotics alone |

FEV₁: forced expiratory volume in 1 s; FVC: forced vital capacity; ICS: inhaled corticosteroid; LABA: long-acting β₂-agonist; LAMA: long-acting muscarinic-receptor antagonist.
glucocorticoids, antibiotics or both) or one or more severe exacerbation (hospitalisation). Those with a history of asthma were excluded. Smoking status and pack-years were not part of the inclusion criteria. In METREX, patients were randomised 1:1 to receive subcutaneous injections of either mepolizumab 100 mg or placebo (0.9% saline), while in METREO patients were randomised 1:1:1 to receive either mepolizumab 100 mg, mepolizumab 300 mg or placebo (0.9% saline) every 4 weeks for 52 weeks. METREX patients were stratified by blood eosinophils at screening visit: either ≥150 cells·μL−1, ≥300 cells·μL−1 at any point in the previous year, or those who were non-eosinophilic (<150 cells·μL−1); while METREO included only those with an eosinophilic phenotype. The primary end-point of both trials was yearly rate of moderate or severe exacerbations. Secondary end-points were time to first exacerbation, emergency department visits, hospitalisation, and average yearly changes in St George’s Respiratory Questionnaire and COPD Assessment Test scores. Results were controlled for smoking status, number of exacerbations in the previous year, baseline disease severity (percentage of predicted FEV1) and geographic region.

**Key results**

**METREX**

836 patients were analysed according to an intention-to-treat analysis. 94% or more patients were Global Initiative for Chronic Obstructive Lung Disease (GOLD) group D COPD (≥2 exacerbations in total, ≥1 leading to hospitalisation, and either a Medical Research Council dyspnoea scale score of ≥2 or a COPD Assessment Test score of ≥10). There was a significant difference in annual exacerbation rates in those with an eosinophilic phenotype (≥150 cells·μL−1 at screening visit or ≥300 cells·μL−1 at any point in the previous year) between the mepolizumab groups and placebo groups (rate ratio 0.82, 95% CI 0.68–0.98; p=0.04). In the undifferentiated population there was no significant difference in exacerbation rates between mepolizumab and placebo (1.49 versus 1.52 per year, respectively). Regarding secondary end-points, those with an eosinophilic phenotype had a significantly increased time to exacerbation (hazard ratio 0.75, 95% CI 0.60–0.94; p=0.04), but there was no significant difference in the undifferentiated population. A pre-specified meta-analysis was performed by stratifying screening blood eosinophil count as follows: <150 and a history of ≥300 cells·μL−1 in the previous year; ≥150 to <300 cells·μL−1, ≥300 to <500 cells·μL−1; and ≥500 cells·μL−1. Patients with higher blood eosinophil count had a greater benefit from mepolizumab. In particular, in those with blood eosinophils ≥300 cells·μL−1, the exacerbation rate was 23% lower in those treated with mepolizumab than placebo.

**METREO**

674 were included in the intention-to-treat protocol. Patients received mepolizumab at 100 mg (low dose), mepolizumab at 300 mg (high dose) or a placebo, with the primary aim of determining optimal dosing of mepolizumab. Similarly, 94% or more patients were GOLD group D COPD patients. METREO did not show any significant benefit from high-dose mepolizumab compared to low-dose mepolizumab in eosinophilic patients.

**Safety**

The most commonly reported side-effects were exacerbations or worsening of COPD, nasopharyngitis, headache and pneumonia. While METREX and METREO had 4% and 3% mortality rates, respectively, rates were comparable with the placebo group. Similarly, there was no significant difference in systemic reaction, injection site reaction or event leading to treatment discontinuation between the groups in either trial.

**Strengths and limitations**

These were the largest trials of targeted IL-5 therapy in COPD. METREX and METREO set out to ask the specific question of whether mepolizumab can reduce the rate of exacerbations in patients with severe COPD. PAVORD et al. [16] have highlighted a population of COPD patients that may specifically benefit from targeted therapy in this form, namely those with raised blood eosinophils who have a high rate of exacerbations despite maximal standard therapy. These studies showed that patients with high blood eosinophils in the context of severe COPD with frequent exacerbations benefit from a 4-weekly 100-mg subcutaneous injection of mepolizumab. This benefit is realised in terms of reduced exacerbation rate and time to next exacerbation. Despite this, lung volumes and quality of life indices were not significantly altered. Although mortality was only measured as part of a composite end-point (i.e. COPD exacerbations), the death rate was low overall and broadly comparable between groups.

Prior to METREX/METREO, BRIGHTLING et al. [12] reported hopeful results on the use of benralizumab, an IL-5 receptor monoclonal antibody, in COPD patients with raised blood eosinophils. They experienced a significant improvement in lung function, albeit with no change in exacerbation rate. The discrepancy in results between mepolizumab and benralizumab is most likely due to differences in trial population. The benralizumab trial population had fewer exacerbations at baseline, had slightly less severe COPD, and included only current smokers or ex-smokers. Similarly, the difference in trial populations may explain why those in the benralizumab trial experienced a significant improvement in pre-bronchodilator FEV1, unlike
with mepolizumab. Interestingly, this may reflect an important relationship between smoking status, blood eosinophils and treatment response. This study by Pavord et al. [16] relies upon stratifying patients by blood eosinophil level at a single time point. This strategy is clinically feasible and applicable to practical medicine. Blood eosinophil levels have been previously demonstrated to be stable over time: Southworth et al. [18] showed that >80% of patients using the blood eosinophil cut-off of 150 cells·μL⁻¹ will remain either eosinophilic or non-eosinophilic after 6 months or 2 years, suggesting that blood eosinophil level is a stable marker of phenotype.

In these two trials, the incidence of pneumonia was higher (9–11%) than in other trials involving a similar cohort of COPD patients (2–7%) [11]. The authors posit that this may be due to all patients taking inhaled corticosteroids. There was no statistically significant difference in the incidence of pneumonia between the mepolizumab and placebo groups in both trials. This potentially highlights the need for steroid-sparing agents in the treatment of COPD.

**Conclusion**

Mepolizumab benefits patients with severe, treatment-resistant COPD who frequently exacerbate and have raised blood eosinophil levels, to reduce the rate of exacerbations and time to next exacerbation. The treatment effect increases with increasing baseline blood eosinophil level. Despite the heterogeneity of COPD, this study draws attention to a phenotype based solely on blood eosinophils, which may benefit from personalised treatment when standard therapies fail short. Further research harnessing the ideals of precision medicine may lead to further unique pathways and a potential agent to replace corticosteroids.

**Conflict of interest**

None declared.

**References**

1. Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. *Eur Respir J* 2014; 44: 1697–1700.
2. Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. *Lancet Respir Med* 2017; 5: 956–967.
3. Kolsum U, Damers G, Pham TH, et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. *J Allergy Clin Immunol* 2017; 140: 1181–1184.
4. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. *Lancet Respir Med* 2015; 3: 435–442.
5. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. *Eur Respir J* 2007; 29: 906–913.
6. Kerkhof M, Sonnappa S, Postma DS, et al. Blood eosinophil count and exacerbation risk in patients with COPD. *Eur Respir J* 2017; 50: 1700761.
7. Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. *Thorax* 2005; 60: 193–198.
8. Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2015; 192: 523–525.
9. Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. *Lancet Respir Med* 2018; 6: 117–126.
10. Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. *Thorax* 2013; 68: 1029–1036.
11. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. *Lancet Respir Med* 2013; 1: 210–223.
12. Brightling CE, Bleeker ER, Panettieri RA Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. *Lancet Respir Med* 2014; 2: 891–901.
13. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med* 2014; 371: 1189–1197.
14. Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. *Cochrane Database Syst Rev* 2017; 9: CD010834.
15. Powell C, Milan SJ, Dwan K, et al. Mepolizumab versus placebo for asthma. *Cochrane Database Syst Rev* 2015; 7: CD010834.
16. Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. *N Engl J Med* 2017; 377: 1613–1629.
17. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 2004; 23: 932–946.
18. Southworth T, Beech G, Foden P, et al. The reproducibility of COPD blood eosinophil counts. *Eur Respir J* 2018; 52: 1800427.